Please login to the form below

Not currently logged in
Email:
Password:

Sanofi loses appeal over Taxotere patents in US

Victory for Hospira and Apotex – makers of generic version of the cancer drug

Sanofi has been unsuccessful in its bid to overturn a 2010 court decision to invalidate two patents on Taxotere, its big-selling cancer drug.

The US Court of Appeals for the Federal Circuit has upheld a lower court ruling that the two patents ('561 and '512) were unenforceable on the grounds that the invention was 'obvious' and that Sanofi had engaged in 'inequitable conduct' in obtaining them.

"We have considered Sanofi's additional arguments for reversing the district court's decision and conclude that they similarly lack merit," says the decision document.

The decision is a victory for generic drugmakers Hospira and Apotex, the defendants in the case and the first companies to market generic versions of Taxotere (docetaxel) in 2010, after the patents were invalidated by the lower court.

Sanofi started legal proceedings against the two firms in 2008 when they filed for approval of their generic versions of the drug.

Both patents relate to a formulation of docetaxel that does not make use of Cremophor, a solvent used in early formulations of the drug that was associated with side effects including hypersensitivity reactions, and a lower amount of ethanol.

They would have provided protection from generic competition until July 3, 2012.

Taxotere sales have been hit hard by generic competition in the US and elsewhere in the world, plunging 57 per cent last year to reach $1.2bn across the globe. In 2010, the company made $1.2bn in Taxotere sales from the US market alone.

Sanofi said in a statement that it was disappointed by the latest ruling and that it was evaluating its options. The company sells Taxotere in more than 100 countries to treat lung, prostate, gastric and head and neck cancer.

11th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics